CA3021550C - Pyrazolopyrimidine compounds, compositions comprising the same and their use as tyrosine kinase inhibitors - Google Patents

Pyrazolopyrimidine compounds, compositions comprising the same and their use as tyrosine kinase inhibitors Download PDF

Info

Publication number
CA3021550C
CA3021550C CA3021550A CA3021550A CA3021550C CA 3021550 C CA3021550 C CA 3021550C CA 3021550 A CA3021550 A CA 3021550A CA 3021550 A CA3021550 A CA 3021550A CA 3021550 C CA3021550 C CA 3021550C
Authority
CA
Canada
Prior art keywords
compound
mmol
alkyl
group
src
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021550A
Other languages
English (en)
French (fr)
Other versions
CA3021550A1 (en
Inventor
Asier Unciti-Broceta
Craig Fraser
Neil O. CARRAGHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Edinburgh
Original Assignee
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Edinburgh filed Critical University of Edinburgh
Publication of CA3021550A1 publication Critical patent/CA3021550A1/en
Application granted granted Critical
Publication of CA3021550C publication Critical patent/CA3021550C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3021550A 2015-05-21 2016-04-15 Pyrazolopyrimidine compounds, compositions comprising the same and their use as tyrosine kinase inhibitors Active CA3021550C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1508747.1A GB201508747D0 (en) 2015-05-21 2015-05-21 Compounds
GB1508747.1 2015-05-21
PCT/GB2016/051057 WO2016185160A1 (en) 2015-05-21 2016-04-15 Compounds

Publications (2)

Publication Number Publication Date
CA3021550A1 CA3021550A1 (en) 2016-11-24
CA3021550C true CA3021550C (en) 2023-10-03

Family

ID=53506149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021550A Active CA3021550C (en) 2015-05-21 2016-04-15 Pyrazolopyrimidine compounds, compositions comprising the same and their use as tyrosine kinase inhibitors

Country Status (8)

Country Link
US (1) US10294227B2 (enExample)
EP (1) EP3298015B1 (enExample)
JP (1) JP6684831B2 (enExample)
CN (1) CN107849050B (enExample)
CA (1) CA3021550C (enExample)
ES (1) ES2780382T3 (enExample)
GB (1) GB201508747D0 (enExample)
WO (1) WO2016185160A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190366331A1 (en) * 2016-12-15 2019-12-05 Tunghai University Assay plate and manufacturing method thereof
SI3612519T1 (sl) 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine
WO2020010204A1 (en) * 2018-07-05 2020-01-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
EP3753944A1 (en) * 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments
WO2021041973A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting compounds
KR20220066290A (ko) * 2019-08-29 2022-05-24 히버셀, 인크. Perk 억제 피롤로피리미딘 화합물
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
TW202321248A (zh) 2021-08-11 2023-06-01 愛丁堡大學 酪胺酸激酶抑制劑
JP2024544558A (ja) * 2021-11-15 2024-12-03 ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド Ｓｒｃ阻害剤としての化合物
US20250241916A1 (en) 2022-04-07 2025-07-31 Nuvectis Pharma, Inc. Tyrosine kinase inhibitors
WO2025101861A1 (en) * 2023-11-08 2025-05-15 Nuvectis Pharma, Inc. Crystalline forms of the tyrosine kinase inhibitor ecf506
WO2025101874A1 (en) * 2023-11-08 2025-05-15 Nuvectis Pharma, Inc. Crystalline salt forms of the tyrosine kinase inhibitor ecf506

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2011094628A1 (en) 2010-01-28 2011-08-04 University Of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
BR112014029718A2 (pt) * 2012-05-31 2017-06-27 Pharmascience Inc inibidores da proteína quinase
CN105451741A (zh) * 2013-08-06 2016-03-30 福建海西新药创制有限公司 布鲁顿酪氨酸激酶的抑制剂

Also Published As

Publication number Publication date
ES2780382T3 (es) 2020-08-25
JP6684831B2 (ja) 2020-04-22
US20180127422A1 (en) 2018-05-10
CN107849050B (zh) 2020-10-13
CA3021550A1 (en) 2016-11-24
EP3298015B1 (en) 2020-01-08
CN107849050A (zh) 2018-03-27
JP2018515563A (ja) 2018-06-14
EP3298015A1 (en) 2018-03-28
WO2016185160A1 (en) 2016-11-24
US10294227B2 (en) 2019-05-21
GB201508747D0 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
EP3298015B1 (en) Pyrazolopyrimidine derivatives
AU2018348241B2 (en) Solid forms of a compound for modulating kinases
US10577366B2 (en) Crystalline forms of a compound that inhibits bromodomain
JP7102012B2 (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
WO2020160193A2 (en) Compounds and uses thereof
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
UA124271C2 (uk) ПІРАЗОЛ[1,5-a]ПІРИМІДИНИ ТА ЇХНІ СОЛІ, ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ РАКУ
AU2016272057A1 (en) Use of pteridinone derivative serving as EGFR inhibitor
JP7109919B2 (ja) Ｕｓｐ７阻害剤化合物及び使用方法
CA2895162C (en) Methods and compositions for inhibiting cnksr1
US9605026B2 (en) Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
ES2675580T3 (es) 1H-pirazol-5-olato sódico sustituido
BR112012033425A2 (pt) pirazoloquinolinas
CA3067695A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN112239459A (zh) 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
CN109476669A (zh) Lim激酶抑制剂
CA2983260C (en) Sulfonamide compounds, compositions and methods for inhibiting cnksr1
CN112209917A (zh) 杂环取代苯基哌嗪(啶)类衍生物在抗抑郁药物中的应用
CA3079029C (en) Solid forms of a compound for modulating kinases
WO2025217320A1 (en) Inhibitors of ripk3 and methods of use thereof
WO2026025042A1 (en) P53 targeting compounds and uses thereof
HK40061811B (en) Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210330

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411